Cardiology

Outcomes-based pricing doesn't cut costs of PCSK9 inhibitors

(HealthDay)—Outcomes-based pricing does not reduce the costs of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, according to a research letter published online April 3 in the Annals of Internal Medicine.

Cardiology

Drug 'melts away' fat inside arteries

A new drug being trialled for treating breast cancer and diabetes has been shown to 'melt away' the fat inside arteries that can cause heart attacks and strokes.

Cardiology

Benefits of continued statin use after adverse reactions

Statins are known to reduce the risk of death and cardiovascular events for people who are at high risk; however, as many as 75 percent of patients discontinue statin therapy within two years, often after reporting an adverse ...

page 12 from 29